Discovering New ISCU Compounds: A Promising Strategy for Developing New Drugs

Target Name: ISCU

NCBI ID: G23479

ISCU

Discovering New ISCU Compounds: A Promising Strategy for Developing New Drugs

The Identification of Systemic Unnatural uracil-rich compounds (ISCU) is a promising strategy for the development of new pharmaceuticals and nutraceuticals. ISCU is a unique metabolite that is generated by the uracil biosynthesis pathway in the human body. It has been shown to have a wide range of physiological functions, including the regulation of DNA replication, cell growth, and cell death. The discovery of ISCU as a potential drug target has the potential to lead to new treatments for a variety of diseases.

background

Identification of Systemic Unnatural uracil-rich compounds (ISCU) is a promising strategy for the development of new pharmaceuticals and nutraceuticals. ISCU is a unique metabolite that is generated by the uracil biosynthesis pathway in the human body. It has been shown to have a wide range of physiological functions, including the regulation of DNA replication, cell growth, and cell death. The discovery of ISCU as a potential drug target has the potential to lead to new treatments for a variety of diseases.

ISCU as a Drug Target

ISCU has been shown to have a wide range of physiological functions that make it an attractive drug target. ISCU has been shown to play a role in the regulation of DNA replication, cell growth, and cell death. It has also been shown to play a role in the regulation of cell cycle progression and the G1/S transition.

One of the key features of ISCU is its ability to interact with DNA. ISCU has been shown to bind to the DNA template in the cell and to regulate the accessibility of the DNA template. This interaction between ISCU and DNA has important implications for the regulation of DNA replication and gene expression.

Another important function of ISCU is its role in cell death. ISCU has been shown to play a role in the regulation of cell death, including apoptosis. ISCU has been shown to interact with the B-cell lymphoma 1 (Bcl-2) protein, which is a protein that has been shown to play a role in the regulation of cell death. This interaction between ISCU and Bcl-2 has important implications for the development of new treatments for B-cell lymphomas.

ISCU as a Biomarker

ISCU has also been shown to be a potential biomarker for a variety of diseases. ISCU has been shown to have a wide range of concentrations in different tissues and fluids, including urine, plasma, and tissue. This makes ISCU an attractive candidate for use as a biomarker for a variety of diseases.

One of the key advantages of ISCU as a biomarker is its ability to be detected in a variety of tissues and fluids. This makes ISCU potentially useful as a diagnostic marker for a variety of diseases. ISCU has also been shown to have a wide range of concentrations in different tissues and fluids, which makes it an attractive candidate for use as a biomarker for a variety of diseases.

Discovery of New ISCU Compounds

The discovery of new ISCU compounds is an important step in the development of new pharmaceuticals and nutraceuticals. ISCU has been shown to have a wide range of physiological functions, including the regulation of DNA replication, cell growth, and cell death. ISCU compounds has the potential to lead to new treatments for a variety of diseases.

One of the most promising strategies for the discovery of new ISCU compounds is the use of combinatorial chemistry. Combinatorial chemistry involves the use of a wide range of compounds and reagents to generate new compounds. By using a combination of different compounds and reagents, it is possible to identify new ISCU compounds that have unique properties and functions.

Another important strategy for the discovery of new ISCU compounds is the use of computational tools. Computational tools have been shown to be effective in the prediction of the structure and function of new ISCU compounds

Protein Name: Iron-sulfur Cluster Assembly Enzyme

Functions: Mitochondrial scaffold protein, of the core iron-sulfur cluster (ISC) assembly complex, that provides the structural architecture on which the [2Fe-2S] clusters are assembled (PubMed:34824239). The core iron-sulfur cluster (ISC) assembly complex is involved in the de novo synthesis of a [2Fe-2S] cluster, the first step of the mitochondrial iron-sulfur protein biogenesis. This process is initiated by the cysteine desulfurase complex (NFS1:LYRM4:NDUFAB1) that produces persulfide which is delivered on the scaffold protein ISCU in a FXN-dependent manner. Then this complex is stabilized by FDX2 which provides reducing equivalents to accomplish the [2Fe-2S] cluster assembly. Finally, the [2Fe-2S] cluster is transferred from ISCU to chaperone proteins, including HSCB, HSPA9 and GLRX5 (PubMed:30031876, PubMed:34824239, PubMed:24971490, PubMed:29576242) (Probable). Exists as two slow interchanging conformational states, a structured (S) and disordered (D) form (PubMed:23940031). May modulate NFS1 desulfurase activity in a zinc-dependent manner (PubMed:30031876). Modulates the interaction between FXN and the cysteine desulfurase complex (PubMed:29576242)

The "ISCU Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISCU comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets